According to our new research study on "Embolization Plugs Market Forecast to 2031 -Global Analysis - by Application, End User, and Geography," the market is anticipated to grow from US$ 315.24 million in 2024 to US$ 564.45 million by 2031; the market is expected to register a CAGR of 8.8% from 2025 to 2031. Embolization Plugs market growth is attributed to the rising prevalence of vascular diseases, growing demand for minimally invasive procedures, and technological advancements in device design drive the adoption of embolization plugs.

Embolization plugs are minimally invasive devices that are placed in blood vessels to close off abnormal or unwanted blood flow. They are used to treat aneurysms, arteriovenous malformations, tumors, and bleeding that is controlled by a local dressing made up of small blood vessels. The demand for minimally invasive procedures, the prevalence of vascular diseases, the technological advancement in the design of the plugs, the rising need for embolization due to cancer, and the increasing adoption of interventional radiology are driving the global embolization plugs market growth. Additionally, the improving healthcare sector and the wider clinical applications are also contributing to the rising embolization plugs market size.

The Embolization Plugs market in North America is segmented into the US, Canada, and Mexico. The North America Embolization Plugs market is expanding owing to several factors. The US holds the largest market share, followed by Canada. The demand for Embolization Plugs in the region is fueled by the rising prevalence of cardiovascular diseases, cancer, and other chronic conditions has increased the demand for minimally invasive treatments, including embolization procedures that rely on plugs for precise vessel occlusion.

According to the American Heart Association's 2025 Heart Disease and Stroke Statistics report, peripheral artery disease (PAD) in the US is estimated to affect 8.5 million adults with prevalence reaching more than 12% of people aged 60 and above. Uterine fibroids happen to approximately 26 million women of reproductive age as reported by Centers for Disease Control and Prevention (CDC) and National Institutes of Health (NIH) in 2023. According to the Society for Vascular Surgery's 2023 epidemiological review, varicose veins are the cause of discomfort in about 23% of the adult population or nearly 40 million people, and the majority of the female population is more prone to it due to hormonal changes during pregnancy.

Recently, several significant changes have been made in embolization, which is becoming a minimally invasive method and a fundamental part of the intervention. In August 2025, Instylla, Inc. got the FDA premarket endorsement for the Embrace Hydrogel Embolic System that is a plug capable of being absorbed by the body and facilitates occlusion in the peripheral vessel accurate with fewer migration risks and it is the best for the intervention of PAD.

The EMBOLISE trial, which appeared in the New England Journal of Medicine in 2025, provides evidence that the combination of middle meningeal artery embolization and surgery results in subdural hematoma recurrence rates that are only half as high (12.2% vs 26.2%) as those of patients receiving surgery alone and this has led to the widespread of neurovascular embolization.

CERENOVUS (Johnson & Johnson) introduced n-BCA systems as part of a procedural kit in March 2024 in order to facilitate aneurysm and AVM treatments with better flow control. The rise in demand for these products is due to the increase in vascular diseases which is mainly caused by the aging population - according to the US Census Bureau 2020, the number of people over 65 is expected to reach 94 million by 2060 - and the risk factors that keep rising simultaneously.

According to CDC, Obesity affects 42% of the adult population and this condition is the main reason for the increase in obesity-related peripheral artery disease by 2060; the prevalence of diabetes has gone up to 14.7% in 2023 (NIH), which is in line with the 39.3% increase in diabetes-related cases by 2060; hypertension is the cause of health problems for 48% (AHA, 2025) of the population, thus, it raised by 25.1%; and dyslipidemia increased by 27.6% as per Globorisk models. The urban sprawl and post-pandemic habits have made the situation worse, though, by making people lead sedentary lifestyles even more than before, and thus, the rate of physical inactivity is at 26% (CDC, 2023). There was a tremendous increase in embolization procedures done by radiologists, that is, 140% growth, since 2005 which can be attributed to the improvement in the screening by ankle-brachial index in primary care as well as guideline changes that promote more early intervention cases. The development in technology such as bioresorbable plugs which lower the chances of recanalization and also the spreading of telemedicine after 2023 are the other factors that contribute to the rise of demand for embolization, which is now considered as a very important vascular tool in the medical sector.

The US Food and Drug Administration, World Bank Data, National Health Service (NHS), FDA (Food and Drug Administration), EMA (European Medicines Agency), National Cancer Institute, Brain Aneurysm Foundation, and Our World in data, and WHO (World Health Organization) are among the primary and secondary sources referred to while preparing the Embolization Plugs market report.